Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Incident Details - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved notable settlements, including the largest securities class action settlement against a Chinese company and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Tandem Diabetes Care Q3 2025 Conference Call Summary Company Overview - **Company**: Tandem Diabetes Care (NasdaqGM:TNDM) - **Date**: November 11, 2025 - **Context**: Discussion of Q3 2025 results and future outlook Key Points Financial Performance - Q3 2025 results showed solid performance with outperformance relative to market expectations, primarily driven by pricing strategies [2][4] - U.S. pump sales experienced a slight decline year-over-year, indicating challenges in the market [2][4] - Pricing improved in Q3, with mid-single-digit year-over-year growth attributed to the pharmacy channel [5][13] Sales and Market Dynamics - The company is undergoing a transformation in the U.S. market, which has led to some turbulence but also signs of improved sales rep productivity [4][11] - September 2025 was noted as the strongest month of the quarter, with expectations for continued sales momentum into Q4 [6][12] - Pharmacy sales accounted for 5% of U.S. revenue in Q3, primarily driven by the introduction of t:slim supplies [7][8] Product Pipeline and Innovations - The company is prioritizing the launch of the tubeless Mobi product, expected to be a significant growth driver in 2026 [18][19] - The integration of Mobi with FreeStyle Libre 3 is anticipated, enhancing product offerings [23] - A fully closed-loop pivotal trial is set to begin in 2026, leveraging existing algorithms and clinical data [24][25] Competitive Landscape - The market is characterized by significant growth potential, with new entrants and competition emerging [34][35] - The company acknowledges the presence of competitors but believes in the overall market opportunity for all players [34] Type 2 Diabetes Market Opportunity - The company is expanding its focus on insulin-intensive Type 2 diabetes patients, which represents a significant market opportunity [42][46] - Current penetration of pumps in this segment is around 5%, with expectations to increase to 25-30% over the next few years [47] International Expansion - Tandem is moving towards a direct sales model in certain international markets, anticipating a minimum 30% ASP premium [51][52] - The transition is expected to be accretive to the bottom line, despite initial OPEX increases [52] Operational Efficiency - The company is implementing measures to improve operational efficiency, including automation and process improvements, which are expected to support a larger install base without proportional increases in headcount [56] 2026 Outlook - Gross margins are projected to improve by at least 300 basis points in 2026, driven by increased pump volumes and pricing benefits [54] - The company is optimistic about achieving OPEX leverage through enhanced sales force productivity and restructuring efforts [56] Additional Insights - The company is cautious about the competitive landscape and is monitoring new entrants closely, indicating a need for time to assess their impact [35][37] - The management emphasized the importance of understanding market dynamics and adapting strategies accordingly, particularly in the context of new product launches and market penetration efforts [41][46]

New York, New York--(Newsfile Corp. - November 10, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

New York, New York--(Newsfile Corp. - November 7, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Tandem Diabetes Care securities you may be entitled to compensation without payment of any out of pocket fees o ...

Core Insights - Tandem Diabetes Care reported Q3 CY2025 results with revenue of $249.3 million, exceeding analyst expectations by 5.6% and showing a year-on-year growth of 2.6% [1][6] - The company's GAAP loss per share was $0.31, which was 3.6% better than the consensus estimate of $0.32 [1][6] Operational Performance - The third quarter was characterized by improved operational efficiency and commercial execution, leading to a positive market reaction [3] - Management attributed the performance to the modernization of U.S. commercial operations, increased pricing contributions, and early traction from new product offerings [3][5] - Changes in sales processes and organizational restructuring have resulted in better sales productivity and a strong customer mix adopting both t:slim and Mobi pump platforms [3] Future Outlook - The company plans to expand pharmacy access, launch new products, and enhance direct international operations [4] - New product introductions, such as Mobi Tubeless and integration with continuous glucose monitoring systems, are expected to drive customer growth [4] - The focus on a fully closed-loop pump system and a multichannel approach is anticipated to improve both top-line and margin performance as the company enters new international markets [4] Financial Metrics - Adjusted EBITDA was reported at $2.77 million, which was a 50% miss compared to analyst estimates of $5.55 million [6] - The operating margin improved to -9.2%, up from -10.7% in the same quarter last year [6] - Sales volumes fell by 4.8% year on year, compared to a decline of 24.7% in the same quarter last year [6] - The company's market capitalization stands at $900.7 million [6]

Financial Data and Key Metrics Changes - In Q3 2025, Tandem Diabetes Care achieved record sales of $249 million, with U.S. sales approximately $176 million, marking the highest third quarter to date and the second highest quarter ever [15][16] - Gross margin increased by 3 percentage points year over year, reaching 54% in Q3, with adjusted EBITDA returning to positive [15][17] - The company ended the quarter with $319 million in total cash and investments, indicating a strong financial position [19] Business Line Data and Key Metrics Changes - Pump shipments in the U.S. were over 20,000, slightly down from Q2 due to pharmacy stocking benefits recognized in the previous quarter [16] - International sales reached $74 million, also a record for Q3, primarily driven by favorable foreign currency exchange rates [17] - Renewals continue to track to a historical capture rate of over 70% of eligible customers within 18 months after warranty expiration [16] Market Data and Key Metrics Changes - The U.S. market saw a significant contribution from pricing, with a 5% increase in Q3, driven by both DME and pharmacy channels [16] - International sales are expected to grow approximately 12% year over year, despite headwinds from distributor inventory destocking [20] Company Strategy and Development Direction - The company is focused on three primary initiatives: modernization of commercial operations, driving innovation, and reshaping the business model [4][10] - Direct sales initiatives in Europe are set to begin in early 2026, with the aim of strengthening financial position and accelerating sales growth [6][20] - The launch of Mobi Tubeless is prioritized, expected to significantly enhance user preference and market presence [26][67] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in 2025, with a target of $1 billion in worldwide sales [20][24] - The company anticipates a strong fourth quarter, with expectations for gross margins in the mid to high 50s [20][59] - Management highlighted the importance of pharmacy access and new product introductions in driving future growth [35][51] Other Important Information - The company has successfully increased pharmacy benefit coverage for Tandem Mobi to over 40% of U.S. lives [11] - A significant focus is placed on enhancing efficiencies and optimizing operations to strengthen operating margins [18][19] Q&A Session Summary Question: Can you provide insights on the cadence of growth for 2026? - Management indicated that multiple initiatives are expected to build momentum throughout 2026, with a focus on Mobi and pharmacy channel expansion [34][36] Question: What is the expected pricing uplift from supplies going through the pharmacy? - Management noted that pricing increases have been a significant contributor to revenue growth, with expectations for continued benefits as pharmacy access expands [39][41] Question: How do you expect Q4 to perform compared to last year? - Management confirmed that Q4 expectations are built on lessons learned from 2024, with a focus on new renewal opportunities [42][44] Question: What percentage of new patient starts were type 2 this quarter? - Management stated that renewals have been slightly more than half of shipments, with MDI conversions making up about two-thirds of new shipments [46][48] Question: Can you clarify the timeline for the Mobi Tubeless launch? - Management confirmed that Mobi Tubeless is expected to enter the market in 2026, pending 510(k) submission approval [90]

Group 1 - The article does not provide any specific information or data regarding companies or industries [1]

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 CY2025 results exceeding the market’s revenue expectations , with sales up 2.2% year on year to $249.3 million. Its GAAP loss of $0.31 per share was 3.6% above analysts’ consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q3 CY2025 Highlights: Revenue: $249.3 million vs analyst estimates of $236 million (2.2% year-on-year growth, 5.6% beat) EPS (GAAP): -$0.31 ...